SARS-CoV-2 and Plasmodium falciparum Co-Infection in a Returning Traveler
Since December 2019, the Coronavirus Disease 2019 (COVID-19) pandemic has become a non-neglectable context for the whole healthcare system. Under the background of COVID-19, the detection and diagnosis of malaria cases are under challenge. Here, we reported a COVID-19 and malaria co-infection travel...
Saved in:
Main Authors: | , , , , , , , , |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_a28a16a8a3a44fff94c29771d12fa7f9 | ||
042 | |a dc | ||
100 | 1 | 0 | |a Qian Huang |e author |
700 | 1 | 0 | |a Wen-Jie Xu |e author |
700 | 1 | 0 | |a Xiao-Xiao Wang |e author |
700 | 1 | 0 | |a Xuan Zhang |e author |
700 | 1 | 0 | |a Ke-Nu Pan |e author |
700 | 1 | 0 | |a Jia-Qi Zhang |e author |
700 | 1 | 0 | |a Hua-Liang Chen |e author |
700 | 1 | 0 | |a Wei Ruan |e author |
700 | 1 | 0 | |a Li-Nong Yao |e author |
245 | 0 | 0 | |a SARS-CoV-2 and Plasmodium falciparum Co-Infection in a Returning Traveler |
260 | |b Frontiers Media S.A., |c 2022-08-01T00:00:00Z. | ||
500 | |a 2296-2565 | ||
500 | |a 10.3389/fpubh.2022.871374 | ||
520 | |a Since December 2019, the Coronavirus Disease 2019 (COVID-19) pandemic has become a non-neglectable context for the whole healthcare system. Under the background of COVID-19, the detection and diagnosis of malaria cases are under challenge. Here, we reported a COVID-19 and malaria co-infection traveler who has a long living history in Cameroon. The case was administered with dihydroartemisinin and piperaquine tablets for malaria, Lopinavir and Ritonavir tablets, Arbidol, recombinant human interferon α-2b and Compound Maxing Yifei mixture for COVID-19, and Zolpidem Tartrate tablets, Diazepam, Paroxetine Hydrochloride tablets, Thymosin α1, and Lianhua Qinwen Jiaonang during the second hospitalization of the patient since the patient has a certain level of anxiety and insomnia with no evidence of inflammatory reactions. After being tested negative two times for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 48 h, the patient met China's COVID-19 discharge standards and was discharged with stable vital signs and mental state. Since most countries in the sub-Saharan region have a fragile health system, co-infection for both Plasmodium and SARS-CoV-2 may not be uncommon, and raise a challenge in diagnosis, treatment, and prevention for both diseases. We add to the literature on co-infection of P. falciparum malaria and COVID-19 and offer operational advice on diagnosis, prevention, and treatment for the co-infection. | ||
546 | |a EN | ||
690 | |a COVID-19 | ||
690 | |a Sub-Saharan Africa | ||
690 | |a co-infection | ||
690 | |a Plasmodium falciparum | ||
690 | |a malaria | ||
690 | |a SARS-CoV-2 | ||
690 | |a Public aspects of medicine | ||
690 | |a RA1-1270 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Frontiers in Public Health, Vol 10 (2022) | |
787 | 0 | |n https://www.frontiersin.org/articles/10.3389/fpubh.2022.871374/full | |
787 | 0 | |n https://doaj.org/toc/2296-2565 | |
856 | 4 | 1 | |u https://doaj.org/article/a28a16a8a3a44fff94c29771d12fa7f9 |z Connect to this object online. |